The combination of chemotherapy and systemic immunotherapy and the concept of cure in murine leukemia and lymphoma.
While important advances have been made in our understanding of the molecular and biochemical processes that lead to the malignant transformation of myeloid and lymphoid cells, no major breakthroughs leading to long-term survival of patients of acute myeloid leukemia (AML) and lymphoma have been achieved during the last decade. Treatment failure, particularly in AML, is mostly related to the problem of resistance to multiple chemotherapeutic drugs and the morbidity and mortality associated with intensive chemotherapy. Thus, a significant challenge that remains is to develop novel therapeutic strategies that would ideally be able to address these issues. Novel immune approaches to cancer immunotherapy, while promising for specificity and long-term protection as single therapies, have not typically proven potent enough to generate long-lasting therapeutic responses. Recent evidence suggests that combining immunotherapy with chemotherapy can lead to increased effectiveness of chemotherapy without making the treatment intolerable to patients. This review focuses on the role of T cell costimulation in tumor immunosurveillance and on the therapeutic efficacy of a combination regimen consisting of chemotherapy and immunotherapy with recombinant B7.2-IgG fusion protein in preclinical AML and lymphoma models.
Dunussi-Joannopoulos
Kyriaki
K
Wyeth Research, 200 Cambridge Park Drive, Cambridge, MA 02140, USA.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018122:B7-1 Antigen / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D007167:Immunotherapy; D007938:Leukemia / Q000628:therapy*; D008213:Lymphocyte Activation / Q000187:drug effects; D008223:Lymphoma / Q000628:therapy*; D051379:Mice
D000970:Antineoplastic Agents; D018122:B7-1 Antigen